ZNF513

Summary

ZNF513 (zinc finger protein 513, HGNC:26498) is a protein-coding gene on chromosome 2p23.3, encoding Zinc finger protein 513 (Q8N8E2). Transcriptional regulator that plays a role in retinal development and maintenance.

The protein encoded by this gene is a possible transcriptional regulator involved in retinal development. Defects in this gene can be a cause of autosomal-recessive retinitis pigmentosa. Two transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 130557 — RefSeq curated summary.

At a glance

• Gene–disease (curated): retinitis pigmentosa 58 (Moderate, GenCC) — +1 more curated relationship
• GWAS associations: 4
• Clinical variants (ClinVar): 473 total — 1 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 37
• MANE Select transcript: NM_144631

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26498
Approved symbol	ZNF513
Name	zinc finger protein 513
Location	2p23.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ32203, RP58, Zfp513
Ensembl gene	ENSG00000163795
Ensembl biotype	protein_coding
OMIM	613598
Entrez	130557

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000323703, ENST00000407879, ENST00000436006, ENST00000491924, ENST00000917778

RefSeq mRNA: 2 — MANE Select: NM_144631 NM_001201459, NM_144631

CCDS: CCDS1751, CCDS56114

Canonical transcript exons

ENST00000323703 — 4 exons

Exon	Start	End
ENSE00001078334	27378467	27379054
ENSE00001333824	27380472	27380734
ENSE00001549663	27377235	27378371
ENSE00003641826	27380093	27380248

Expression profiles

Bgee: expression breadth ubiquitous, 222 present calls, max score 90.87.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.8216 / max 50.0734, expressed in 1498 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
27493	3.8216	1498

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right testis	UBERON:0004534	90.87	gold quality
left testis	UBERON:0004533	90.54	gold quality
adenohypophysis	UBERON:0002196	90.06	gold quality
granulocyte	CL:0000094	89.40	gold quality
lower esophagus mucosa	UBERON:0035834	89.15	gold quality
mucosa of transverse colon	UBERON:0004991	88.75	gold quality
right lobe of liver	UBERON:0001114	88.72	gold quality
body of stomach	UBERON:0001161	88.38	gold quality
metanephros cortex	UBERON:0010533	88.36	gold quality
pituitary gland	UBERON:0000007	88.28	gold quality
oocyte	CL:0000023	87.63	gold quality
transverse colon	UBERON:0001157	87.59	gold quality
cortical plate	UBERON:0005343	87.31	gold quality
testis	UBERON:0000473	87.25	gold quality
right adrenal gland cortex	UBERON:0035827	87.15	gold quality
right lobe of thyroid gland	UBERON:0001119	87.13	gold quality
left adrenal gland cortex	UBERON:0035825	87.06	gold quality
small intestine Peyer’s patch	UBERON:0003454	87.04	gold quality
right adrenal gland	UBERON:0001233	86.92	gold quality
mucosa of stomach	UBERON:0001199	86.82	gold quality
left lobe of thyroid gland	UBERON:0001120	86.77	gold quality
left adrenal gland	UBERON:0001234	86.69	gold quality
lower esophagus muscularis layer	UBERON:0035833	86.61	gold quality
lower esophagus	UBERON:0013473	86.60	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	86.51	gold quality
right frontal lobe	UBERON:0002810	86.33	gold quality
right hemisphere of cerebellum	UBERON:0014890	86.33	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.06	gold quality
adrenal cortex	UBERON:0001235	86.01	gold quality
prefrontal cortex	UBERON:0000451	85.99	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.14

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
ARR3

miRNA regulators (miRDB)

27 targeting ZNF513, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-142-5P	99.48	70.92	2416
HSA-MIR-5590-3P	99.48	70.91	2429
HSA-MIR-122B-5P	99.46	70.81	1457
HSA-MIR-3911	99.38	66.95	1087
HSA-MIR-361-3P	99.19	66.45	1381
HSA-MIR-331-3P	98.76	64.91	793
HSA-MIR-6878-5P	98.49	67.91	2142
HSA-MIR-1304-3P	98.29	66.44	1207
HSA-MIR-33B-3P	97.92	67.39	529
HSA-MIR-515-3P	97.92	67.98	506
HSA-MIR-519E-3P	97.92	68.25	508
HSA-MIR-7847-3P	96.63	64.58	952
HSA-MIR-7160-3P	96.40	64.15	462

Literature-anchored findings (GeneRIF, showing 2)

• These results suggest that the ZNF513 p.C339R mutation is responsible for retinitis pigmentosa and that ZNF513 plays a key role in the regulation of photoreceptor-specific genes in retinal development and photoreceptor maintenance. (PMID:20797688)
• Double heterozygous pathogenic mutations in KIF3C and ZNF513 cause hereditary gingival fibromatosis. (PMID:37752101)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	znf513a	ENSDARG00000019961
danio_rerio	znf513b	ENSDARG00000101203
mus_musculus	Zfp513	ENSMUSG00000043059
rattus_norvegicus	Zfp513	ENSRNOG00000005298
drosophila_melanogaster	dwg	FBGN0000520
drosophila_melanogaster	CG6654	FBGN0038301
caenorhabditis_elegans		WBGENE00003933

Paralogs (6): ZNF324 (ENSG00000083812), ZBTB47 (ENSG00000114853), GTF3A (ENSG00000122034), ZUP1 (ENSG00000153975), ZNF652 (ENSG00000198740), ZNF324B (ENSG00000249471)

Protein

Protein identifiers

Zinc finger protein 513 — Q8N8E2 (reviewed: Q8N8E2)

All UniProt accessions (2): C9JT52, Q8N8E2

UniProt curated annotations — full annotation on UniProt →

Function. Transcriptional regulator that plays a role in retinal development and maintenance.

Subunit / interactions. Binds DNA. Can associate with the proximal promoter regions of PAX6 and SP4, and their known targets including ARR3, RHO, OPN1MW2 and OPN1SW.

Subcellular location. Nucleus.

Tissue specificity. In the retina, expressed in the outer and inner nuclear layers, and the ganglion cell layer.

Disease relevance. Retinitis pigmentosa 58 (RP58) [MIM:613617] A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8N8E2-1	1	yes
Q8N8E2-2	2
Q8N8E2-3	3

RefSeq proteins (2): NP_001188388, NP_653232* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096

UniProt features (21 total): zinc finger region 8, sequence conflict 3, region of interest 2, compositionally biased region 2, modified residue 2, splice variant 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N8E2-F1	60.20	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 85, 96

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 147 (showing top): LFA1_Q6, GGGTGGRR_PAX4_03, CAGCTG_AP4_Q5, SRF_Q5_01, CATRRAGC_UNKNOWN, SRF_C, GGAANCGGAANY_UNKNOWN, GOBP_SENSORY_PERCEPTION_OF_LIGHT_STIMULUS, HEN1_01, GRE_C, LXR_Q3, GOBP_SENSORY_PERCEPTION, VDR_Q3, GOBP_SENSORY_ORGAN_DEVELOPMENT, CCAGGGG_MIR331

GO Biological Process (3): visual perception (GO:0007601), positive regulation of transcription by RNA polymerase II (GO:0045944), retina development in camera-type eye (GO:0060041)

GO Molecular Function (5): transcription cis-regulatory region binding (GO:0000976), DNA binding (GO:0003677), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
sensory perception of light stimulus	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
camera-type eye development	1
anatomical structure development	1
transcription regulatory region nucleic acid binding	1
sequence-specific double-stranded DNA binding	1
nucleic acid binding	1
transition metal ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

740 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF513	IMPG2	Q9BZV3	807
ZNF513	PRCD	Q00LT1	806
ZNF513	PCARE	A6NGG8	801
ZNF513	PDE6G	P18545	792
ZNF513	CERKL	Q49MI3	780
ZNF513	EYS	Q5T1H1	761
ZNF513	FSCN2	O14926	751
ZNF513	SNRNP200	O75643	749
ZNF513	IDH3B	O43837	749
ZNF513	PDE6A	P16499	746
ZNF513	PRPF3	O43395	745
ZNF513	PRPF31	Q8WWY3	742
ZNF513	CNGB1	Q14028	738
ZNF513	RP9	Q8TA86	738
ZNF513	TTC8	Q8TAM2	733

IntAct

17 interactions, top by confidence:

A	B	Type	Score
KAT5	ZNF513	psi-mi:“MI:0915”(physical association)	0.560
ZNF513	KAT5	psi-mi:“MI:0915”(physical association)	0.560
ZNF513	DNMT3A	psi-mi:“MI:0915”(physical association)	0.560
ZNF513	UQCRC1	psi-mi:“MI:0915”(physical association)	0.560
ZNF513	RRBP1	psi-mi:“MI:0915”(physical association)	0.400
ZNF513	ZNF513	psi-mi:“MI:0915”(physical association)	0.370
ZZZ3	ZNF513	psi-mi:“MI:0915”(physical association)	0.370
ZFP64	ZNF513	psi-mi:“MI:0915”(physical association)	0.370
ZNF513	PPARGC1B	psi-mi:“MI:0915”(physical association)	0.370
SLC11A1	TRAFD1	psi-mi:“MI:0914”(association)	0.350
DNMT3A	ZNF513	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (9): ZNF513 (Two-hybrid), ZNF513 (Two-hybrid), RRBP1 (Proximity Label-MS), ZNF513 (Affinity Capture-MS), ZNF513 (Affinity Capture-RNA), ZNF513 (Two-hybrid), ZNF513 (Two-hybrid), ZNF513 (Two-hybrid), PPARGC1B (Two-hybrid)

ESM2 similar proteins: A2CE44, A6NFI3, A6NM28, A8K8V0, O15370, O70218, O95201, P0CJ78, P10075, P10754, P28698, P70338, Q04890, Q07120, Q14V87, Q19A40, Q569E7, Q58DK7, Q5DWN0, Q5FWU5, Q5RJR4, Q5T619, Q5TEC3, Q6DD87, Q6IQX8, Q6PD29, Q6PGE4, Q6ZMY9, Q7Z7K2, Q80VM4, Q8BIF9, Q8JZL0, Q8N8E2, Q8NAF0, Q8NCA9, Q8TD94, Q8WUU4, Q96C55, Q96H86, Q96MX3

Diamond homologs: Q5FWU5, Q6PD29, Q8N8E2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

473 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	297
Likely benign	144
Benign	2

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
3248931	NM_144631.6(ZNF513):c.423dup (p.Pro142fs)	Pathogenic
930689	NM_144631.6(ZNF513):c.279_283del (p.Ala94fs)	Likely pathogenic

SpliceAI

985 predictions. Top by Δscore:

Variant	Effect	Δscore
2:27378780:CGAG:C	acceptor_gain	1.0000
2:27378781:G:T	acceptor_gain	1.0000
2:27378783:G:GC	acceptor_gain	1.0000
2:27378792:C:CT	acceptor_gain	1.0000
2:27378794:C:CT	acceptor_gain	1.0000
2:27380088:CCCA:C	donor_loss	1.0000
2:27380089:CCA:C	donor_loss	1.0000
2:27380090:CACCT:C	donor_loss	1.0000
2:27380091:A:AG	donor_loss	1.0000
2:27380091:ACCTT:A	donor_gain	1.0000
2:27380092:CCTTC:C	donor_gain	1.0000
2:27380095:T:A	donor_gain	1.0000
2:27380249:C:CC	acceptor_gain	1.0000
2:27380480:C:CA	donor_gain	1.0000
2:27380514:T:TA	donor_gain	1.0000
2:27378783:G:C	acceptor_gain	0.9900
2:27378786:G:C	acceptor_gain	0.9900
2:27378786:G:GC	acceptor_gain	0.9900
2:27378795:G:T	acceptor_gain	0.9900
2:27378799:G:GC	acceptor_gain	0.9900
2:27378964:A:C	donor_gain	0.9900
2:27379054:CCTGG:C	acceptor_gain	0.9900
2:27380091:A:AC	donor_gain	0.9900
2:27380092:C:CC	donor_gain	0.9900
2:27380092:CCTT:C	donor_gain	0.9900
2:27380245:TCCA:T	acceptor_gain	0.9900
2:27380246:CCA:C	acceptor_gain	0.9900
2:27380246:CCAC:C	acceptor_gain	0.9900
2:27380247:CA:C	acceptor_gain	0.9900
2:27380247:CAC:C	acceptor_gain	0.9900

AlphaMissense

3493 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:27377703:G:C	H490D	1.000
2:27377751:A:G	C474R	1.000
2:27377773:G:C	H466Q	1.000
2:27377773:G:T	H466Q	1.000
2:27377785:G:C	H462Q	1.000
2:27377785:G:T	H462Q	1.000
2:27377787:G:C	H462D	1.000
2:27377787:G:T	H462N	1.000
2:27377795:A:G	L459P	1.000
2:27377797:G:C	N458K	1.000
2:27377797:G:T	N458K	1.000
2:27377814:A:G	C453R	1.000
2:27377835:A:G	C446R	1.000
2:27377839:A:C	F444L	1.000
2:27377839:A:T	F444L	1.000
2:27377841:A:G	F444L	1.000
2:27377871:G:C	H434D	1.000
2:27377871:G:T	H434N	1.000
2:27377879:A:G	L431P	1.000
2:27377881:G:C	N430K	1.000
2:27377881:G:T	N430K	1.000
2:27377919:A:G	C418R	1.000
2:27377955:G:C	H406D	1.000
2:27377955:G:T	H406N	1.000
2:27377965:G:C	N402K	1.000
2:27377965:G:T	N402K	1.000
2:27378039:G:C	H378D	1.000
2:27377701:G:C	H490Q	0.999
2:27377701:G:T	H490Q	0.999
2:27377703:G:T	H490N	0.999

dbSNP variants (sampled 300 via entrez): RS1000337026 (2:27379508 G>A), RS1000959532 (2:27380591 G>A,C), RS1001343740 (2:27378379 G>A,C), RS1002035250 (2:27380549 CGCCTCCG>C), RS1003013705 (2:27379068 CATA>C), RS1003046380 (2:27379281 T>A), RS1003249202 (2:27381072 C>A,G), RS1003497741 (2:27381359 A>G), RS1004503387 (2:27377381 C>G,T), RS1005000807 (2:27381099 C>A,G,T), RS1005858970 (2:27380570 C>T), RS1005911394 (2:27380335 T>G), RS1006911209 (2:27379139 C>T), RS1007269814 (2:27379458 T>C), RS1008917601 (2:27377152 C>G)

Disease associations

OMIM: gene MIM:613598 | disease phenotypes: MIM:613617, MIM:268000

GenCC curated gene-disease

Disease	Classification	Inheritance
retinitis pigmentosa 58	Moderate	Autosomal recessive
retinitis pigmentosa	Supportive	Autosomal dominant

Mondo (4): retinitis pigmentosa 58 (MONDO:0013328), inherited retinal dystrophy (MONDO:0019118), retinitis pigmentosa (MONDO:0019200), optic atrophy (MONDO:0003608)

Orphanet (2): Retinitis pigmentosa (Orphanet:791), OBSOLETE: Inherited retinal disorder (Orphanet:71862)

HPO phenotypes

37 total (30 of 37 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000405	Conductive hearing impairment
HP:0000407	Sensorineural hearing impairment
HP:0000501	Glaucoma
HP:0000505	Visual impairment
HP:0000510	Rod-cone dystrophy
HP:0000512	Abnormal electroretinogram
HP:0000543	Optic disc pallor
HP:0000546	Retinal degeneration
HP:0000551	Color vision defect
HP:0000563	Keratoconus
HP:0000602	Ophthalmoplegia
HP:0000608	Macular degeneration
HP:0000613	Photophobia
HP:0000618	Blindness
HP:0000639	Nystagmus
HP:0000648	Optic atrophy
HP:0000662	Nyctalopia
HP:0000842	Hyperinsulinemia
HP:0001105	Retinal atrophy
HP:0001141	Severely reduced visual acuity
HP:0003621	Juvenile onset
HP:0007663	Reduced visual acuity
HP:0007675	Progressive night blindness
HP:0007703	Abnormal retinal pigmentation
HP:0007737	Spicular pigmentation of the retina
HP:0007787	Posterior subcapsular cataract
HP:0007843	Attenuation of retinal blood vessels
HP:0007994	Peripheral visual field loss
HP:0008046	Abnormal retinal vascular morphology

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST004131_72	Inflammatory bowel disease	1.000000e-07
GCST004132_64	Crohn’s disease	6.000000e-11
GCST010107_9	L-selectin levels	5.000000e-06
GCST010134_1	Non-oily fish consumption	9.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0008202	L-Selectin measurement
EFO:0008111	diet measurement

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D009896	Optic Atrophy	C10.292.700.225; C11.640.451
D058499	Retinal Dystrophies	C11.768.585.658
D012174	Retinitis Pigmentosa	C11.270.684; C11.768.585.658.500; C16.320.290.684

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression	4
Cyclosporine	decreases expression, increases expression	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
FR900359	increases phosphorylation	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
beta-lapachone	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
butyraldehyde	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
Sunitinib	decreases expression	1
Vehicle Emissions	decreases expression, increases abundance	1
Benzo(a)pyrene	increases expression	1
Caffeine	increases phosphorylation	1
Doxorubicin	decreases expression	1
Quercetin	increases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	increases expression	1
Acrylamide	increases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

259 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00000114	PHASE3	COMPLETED	Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
NCT00000116	PHASE3	COMPLETED	Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
NCT00346333	PHASE3	COMPLETED	Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
NCT01786395	PHASE3	TERMINATED	Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
NCT04224207	PHASE3	COMPLETED	Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton’s Jelly Derived Mesenchymal Stem Cells
NCT04636853	PHASE3	COMPLETED	CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
NCT05537220	PHASE3	ACTIVE_NOT_RECRUITING	Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05800301	PHASE3	COMPLETED	Management of Retinitis Pigmentosa Via Combination of Wharton’s Jelly-derived Mesenchymal Stem Cells and Magnovision
NCT05926583	PHASE3	ACTIVE_NOT_RECRUITING	A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
NCT06388200	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT07082855	PHASE3	NOT_YET_RECRUITING	A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
NCT07290530	PHASE3	NOT_YET_RECRUITING	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT00100230	PHASE2	COMPLETED	DHA and X-Linked Retinitis Pigmentosa
NCT00447980	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447993	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT01233609	PHASE2	COMPLETED	Trial of Oral Valproic Acid for Retinitis Pigmentosa
NCT01399515	PHASE2	COMPLETED	Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
NCT01530659	PHASE2	COMPLETED	Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
NCT01560715	PHASE2	COMPLETED	Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
NCT02609165	PHASE2	COMPLETED	Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
NCT02661711	PHASE2	COMPLETED	Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
NCT02804360	PHASE2	UNKNOWN	Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study
NCT02837640	PHASE2	UNKNOWN	Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa
NCT03073733	PHASE2	COMPLETED	Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
NCT04068207	PHASE2	COMPLETED	Minocycline Treatment in Retinitis Pigmentosa
NCT04356716	PHASE2	COMPLETED	Sildenafil for Treatment of Choroidal Ischemia
NCT04604899	PHASE2	COMPLETED	Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
NCT04763369	PHASE2	UNKNOWN	Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)
NCT04864496	PHASE2	UNKNOWN	Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa
NCT04945772	PHASE2	COMPLETED	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
NCT05085964	PHASE2	TERMINATED	An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
NCT05392179	PHASE2	COMPLETED	A Study in Subjects With Retinitis Pigmentosa
NCT06627179	PHASE2	RECRUITING	Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06628947	PHASE2	RECRUITING	A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
NCT06912633	PHASE2	RECRUITING	Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
NCT03763227	PHASE2	COMPLETED	Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy
NCT00063765	PHASE1	COMPLETED	Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye
NCT00065455	PHASE1	COMPLETED	Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
NCT00458575	PHASE1	TERMINATED	A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa